Finland's institute for health and welfare has said that the country will pause the use of Moderna's (Nasdaq:MRNA) COVID-19 vaccine for men born in 1991 and later due to reports of a rare cardiovascular side effect, Reuters news agency reported on Thursday.
The director of the health institute, Mika Salminen, stated: "A Nordic study involving Finland, Sweden, Norway and Denmark found that men under the age of 30 who received Moderna Spikevax had a slightly higher risk than others of developing myocarditis."
This condition, an inflammation of the heart muscle, usually heals on its own in a few days. However, as a precaution Finland would only give Pfizer's (NYSE:PFE) vaccine to boys and young men, Salminen said.
Sweden and Denmark have suspended the use of the Moderna vaccine for all young adults and children.
Xenogenic Materials Demonstrate Promising Results in Peri-Implantitis Management
European Commission approves Celltrion's Remsima IV liquid formulation
Biotheryx completes enrolment in ongoing Phase 1a trial of BTX-9341 for HR+/HER2- breast cancer
Henlius and Organon secure first US approval for pertuzumab biosimilar POHERDY
CHMP issues positive opinion for DAWNZERA in hereditary angioedema
Longeveron secures US patent for stem cell therapy targeting aging-related frailty
Vascarta and CUNY report positive preclinical results in glioblastoma treatment